| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 631 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | CTRVP Hepion Pharmaceuticals, Inc. | Purcell Michael J. | Director | Buy | 1,250,000 | $0.04 | $50,000.00 | New | |
| Apr 21, 2026 | KPTI Karyopharm Therapeutics Inc. | Rangwala Reshma67 | EVP &Chief Medical Officer | Sell | 449 | $8.94 | $4,014.06 | -0.8% | |
| Apr 21, 2026 | BCDA Biocardia, Inc. | Altman Peter46 | President And CEO | Buy | 1,000 | $1.23 | $1,230.00 | +0.2% | |
| Apr 21, 2026 | ADPT Adaptive Biotechnologies Corporation | Rubinstein Julie84 | President And COO | Sell | 69,061 | $14.60 | $1,008,622.26 | -5.4% | |
| Apr 20, 2026 | BLTE Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | Sell | 1,000 | $163.59 | $163,594.55 | -1.1% | |
| Apr 20, 2026 | ROIV Roivant Sciences Ltd. | Venker Eric | President &Immunovant CEO | Sell | 200,000 | $29.59 | $5,918,000.00 | -10.8% | |
| Apr 20, 2026 | TRAXV First Tracks Biotherapeutics, Inc. | Ecor1 Capital, LLC74 | 10% Owner | Sell | 4,705,575 | $13.81 | $64,999,989.71 | -59.7% | |
| Apr 20, 2026 | ATAI Ataibeckley Inc. | Craig Kevin James | Chief Medical Officer | Sell | 42,579 | $5.00 | $212,895.00 | -83.5% | |
| Apr 20, 2026 | VOR Vor Biopharma Inc. | Ra Capital Management, L.P.53 | Director, 10% Owner | Sell | 630,374 | $16.14 | $10,174,787.59 | -10.6% | |
| Apr 20, 2026 | BCAX Bicara Therapeutics Inc. | Mazumdar Claire52 | Chief Executive Officer | Sell | 15,000 | $23.61 | $354,145.50 | -4.0% | |
| Apr 20, 2026 | ONCO Onconetix, Inc. | Hrt Financial LP45 | 10% Owner | Sell | 148,329 | $0.74 | $110,169.41 | -39.6% | |
| Apr 18, 2026 | SION Sionna Therapeutics, Inc. | Orbimed Advisors LLC67 | Director | Sell | 55,345 | $44.67 | $2,472,342.92 | -0.9% | |
| Apr 18, 2026 | SION Sionna Therapeutics, Inc. | Thompson Peter A.65 | Director | Sell | 55,345 | $44.67 | $2,472,342.92 | -0.9% | |
| Apr 17, 2026 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise63 | Chief Medical Officer | Sell | 5,000 | $47.67 | $238,352.42 | -5.7% | |
| Apr 17, 2026 | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% Owner | Sell | 426,005 | $40.32 | $17,175,243.59 | -6.0% | |
| Apr 17, 2026 | MLYS Mineralys Therapeutics, Inc. | Rodman David Malcom56 | Chief Medical Officer | Sell | 416 | $31.33 | $13,033.28 | -0.6% | |
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L46 | Chief Executive Officer | Sell | 9,550 | $20.22 | $193,065.67 | -2.0% | |
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Piekos Brian | Chief Financial Officer | Sell | 1,862 | $20.22 | $37,642.75 | -9.3% | |
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | Chief Medical Officer | Sell | 2,686 | $20.22 | $54,300.98 | -1.8% | |
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | Sell | 1,862 | $20.22 | $37,642.75 | -3.5% | |
| Apr 17, 2026 | ONCO Onconetix, Inc. | Hrt Financial LP45 | 10% Owner | Buy | 34,636 | $0.73 | $25,284.28 | +24.2% | |
| Apr 16, 2026 | TRAW Traws Pharma, Inc. | Orbimed Advisors LLC67 | 10% Owner | Buy | 597,729 | $1.67 | $998,207.43 | +98.7% | |
| Apr 16, 2026 | AURA Aura Biosciences, Inc. | Kilroy Conor | See Remarks | Sell | 11,738 | $7.02 | $82,400.76 | -5.1% | |
| Apr 16, 2026 | ALEC Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | Sell | 1,820 | $2.65 | $4,823.00 | -1.7% | |
| Apr 16, 2026 | PHVS Pharvaris N.V. | Modig Berndt | Chief Executive Officer | Sell | 2,292 | $28.60 | $65,558.53 | -1.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.